DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: DP303c
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.